Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)

Condition:   Lung Cancer, Nonsmall Cell Interventions:   Drug: Pembrolizumab;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Pemetrexed Sponsor:   McGill University Health Centre/Research Institute of the McGill University Health Centre Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials